Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 393
Inquire Before Buying

Global Markets Direct's, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016', provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)

  • The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects

  • The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Congestive Heart Failure (Heart Failure) Overview 12
Therapeutics Development 13
Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview 13
Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis 14
Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies 15
Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes 21
Congestive Heart Failure (Heart Failure) - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Congestive Heart Failure (Heart Failure) - Products under Development by Companies 27
Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes 34
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 36
Amgen Inc. 36
AnGes MG, Inc. 37
Araim Pharmaceuticals, Inc. 38
ARCA biopharma, Inc. 39
Ascelegen Therapeutics, Inc. 40
Asterias Biotherapeutics, Inc. 41
Athersys, Inc. 42
Bayer AG 43
BEAT BioTherapeutics Corp. 44
BioCardia, Inc. 45
Bristol-Myers Squibb Company 46
Capricor Therapeutics, Inc. 47
Cell Therapy Limited 48
Celyad SA 49
Eli Lilly and Company 50
FibroGen, Inc. 51
GlaxoSmithKline Plc 52
Glucox Biotech AB 53
Heart Metabolics Limited 54
Hemostemix Ltd 55
Innopharmax Inc. 56
Jiangsu Hengrui Medicine Co., Ltd. 57
Juventas Therapeutics, Inc. 58
La Jolla Pharmaceutical Company 59
Laboratoires Pierre Fabre SA 60
Lead Discovery Center GmbH 61
Lee's Pharmaceutical Holdings Limited 62
Les Laboratoires Servier SAS 63
Lonestar Heart, Inc. 64
Mast Therapeutics, Inc. 65
Merck & Co., Inc. 66
Mesoblast Limited 67
miRagen Therapeutics, Inc. 68
MorphoSys AG 69
NanoCor Therapeutics, Inc. 70
Neurocrine Biosciences, Inc. 71
Novartis AG 72
Nuo Therapeutics, Inc. 73
Ono Pharmaceutical Co., Ltd. 74
Palatin Technologies, Inc. 75
Pfizer Inc. 76
PharmaIN Corporation 77
PhaseBio Pharmaceuticals, Inc. 78
Pluristem Therapeutics Inc. 79
Quantum Genomics SA 80
Recardio GmbH 81
RedHill Biopharma Ltd. 82
Renova Therapeutics Inc 83
scPharmaceuticals Inc 84
Stealth BioTherapeutics Inc. 85
Stemedica Cell Technologies, Inc. 86
Target Heart Biotec Srl 87
Theravance Biopharma, Inc. 88
TiGenix NV 89
Torrent Pharmaceuticals Limited 90
Trevena, Inc. 91
U.S. Stem Cell, Inc. 92
Vichem Chemie Research Ltd. 93
Vicore Pharma AB 94
Zensun (Shanghai) Sci & Tech Co., Ltd. 95
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 96
Assessment by Monotherapy Products 96
Assessment by Combination Products 97
Assessment by Target 98
Assessment by Mechanism of Action 104
Assessment by Route of Administration 110
Assessment by Molecule Type 112
Drug Profiles 114
(sacubitril + valsartan) - Drug Profile 114
AAVS-100A1 - Drug Profile 119
ACP-01 - Drug Profile 121
AdipoCell - Drug Profile 124
aladorian sodium - Drug Profile 127
ALD-201 - Drug Profile 129
AMG-986 - Drug Profile 131
AntimiR-199a - Drug Profile 132
ARX-720 - Drug Profile 133
BAY-868050 - Drug Profile 134
BBR-12 - Drug Profile 135
beperminogene perplasmid - Drug Profile 136
BMS-986231 - Drug Profile 141
bucindolol hydrochloride - Drug Profile 142
C-21 - Drug Profile 149
C3BSCQR-1 - Drug Profile 151
CAP-1002 - Drug Profile 156
Carfostin - Drug Profile 161
carvedilol CR - Drug Profile 162
carvedilol phosphate CR - Drug Profile 164
cenderitide - Drug Profile 165
cibinetide - Drug Profile 168
CLR-325 - Drug Profile 171
CM-1 - Drug Profile 172
CTX-101 - Drug Profile 174
Drug to Inhibit Calpain for Heart Failure - Drug Profile 176
Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure - Drug Profile 177
Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 178
ECR-A1 - Drug Profile 179
elamipretide - Drug Profile 180
enalapril maleate - Drug Profile 187
F-373280 - Drug Profile 188
FG-6874 - Drug Profile 189
FG-8205 - Drug Profile 190
furosemide - Drug Profile 191
GDF-11 - Drug Profile 193
Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 194
Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile 195
Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 196
Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 197
Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile 198
Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 199
GSK-2798745 - Drug Profile 200
istaroxime - Drug Profile 201
ITD-1 - Drug Profile 203
ivabradine hydrochloride - Drug Profile 204
ivabradine hydrochloride SR - Drug Profile 206
JVS-100 - Drug Profile 207
KBP-5074 - Drug Profile 212
L-2286 - Drug Profile 213
MGN-9103 - Drug Profile 214
milrinone ER - Drug Profile 216
Monoclonal Antibody to Inhibit Periostin1 for Congestive Heart Failure - Drug Profile 217
MP-3167 - Drug Profile 218
MPC-150IM - Drug Profile 219
MRS-2339 - Drug Profile 224
MyoCell - Drug Profile 225
MyoCell SDF-1 - Drug Profile 227
NBI-69734 - Drug Profile 228
neladenoson bialanate - Drug Profile 229
Neucardin - Drug Profile 230
NM-922 - Drug Profile 233
NPA-7 - Drug Profile 234
Oligonucleotides for Heart Failure - Drug Profile 235
omecamtiv mecarbil MR - Drug Profile 236
ONO-4232 - Drug Profile 243
PB-1046 - Drug Profile 244
Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 246
Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 247
perhexiline maleate - Drug Profile 248
PF-05285401 - Drug Profile 250
PHIN-1138 - Drug Profile 261
PL-3994 - Drug Profile 262
PLX-PAD - Drug Profile 264
poloxamer - Drug Profile 273
pyroglutaminated serpinin - Drug Profile 275
QGC-101 - Drug Profile 276
REC-02 - Drug Profile 277
Recombinant Protein for Congestive Heart Failure - Drug Profile 278
rivaroxaban - Drug Profile 279
RT-100 - Drug Profile 293
RT-110 - Drug Profile 294
RT-300 - Drug Profile 295
RT-400 - Drug Profile 296
ruboxistaurin - Drug Profile 297
S-38844 - Drug Profile 299
serelaxin - Drug Profile 300
serpinin - Drug Profile 304
SG-1002 - Drug Profile 305
sildenafil citrate - Drug Profile 306
Small Molecule for Target RhoGEF12 for Cardiovascular Disease - Drug Profile 308
Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 309
Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile 310
Small Molecule to Inhibit ROMK for Hypertension and Heart Failure - Drug Profile 311
Small Molecules for Chronic Heart Failure - Drug Profile 312
Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 313
Small Molecules for Diastolic Heart Failure - Drug Profile 314
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 315
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 316
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 317
Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 318
Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile 319
Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 320
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 321
Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 322
sodium nitrite - Drug Profile 323
SP-20202 - Drug Profile 326
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 327
Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 332
Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 333
Stem Cell Therapy for Heart failure - Drug Profile 334
Stem Cell Therapy for Heart Failure - Drug Profile 335
Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 336
Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 337
Synthetic Peptide to Agonise Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile 338
Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile 339
TD-0714 - Drug Profile 340
TR-4 - Drug Profile 342
TRC-4186 - Drug Profile 343
TRV-120023 - Drug Profile 345
ularitide - Drug Profile 346
VCP-746 - Drug Profile 348
vepoloxamer - Drug Profile 349
vericiguat - Drug Profile 357
Xcel-hCardP - Drug Profile 358
XEN-105 - Drug Profile 359
Congestive Heart Failure (Heart Failure) - Dormant Projects 360
Congestive Heart Failure (Heart Failure) - Discontinued Products 370
Congestive Heart Failure (Heart Failure) - Product Development Milestones 372
Featured News & Press Releases 372
Appendix 383
Methodology 383
Coverage 383
Secondary Research 383
Primary Research 383
Expert Panel Validation 383
Contact Us 383
Disclaimer 384

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2016 22
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 25
Number of Products under Development by Companies, H2 2016 (Contd..1) 26
Number of Products under Development by Companies, H2 2016 (Contd..2) 27
Number of Products under Development by Companies, H2 2016 (Contd..3) 28
Number of Products under Development by Companies, H2 2016 (Contd..4) 29
Number of Products under Investigation by Universities/Institutes, H2 2016 31
Comparative Analysis by Late Stage Development, H2 2016 32
Comparative Analysis by Clinical Stage Development, H2 2016 33
Comparative Analysis by Early Stage Development, H2 2016 34
Comparative Analysis by Unknown Stage Development, H2 2016 35
Products under Development by Companies, H2 2016 36
Products under Development by Companies, H2 2016 (Contd..1) 37
Products under Development by Companies, H2 2016 (Contd..2) 38
Products under Development by Companies, H2 2016 (Contd..3) 39
Products under Development by Companies, H2 2016 (Contd..4) 40
Products under Development by Companies, H2 2016 (Contd..5) 41
Products under Development by Companies, H2 2016 (Contd..6) 42
Products under Investigation by Universities/Institutes, H2 2016 43
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 44
Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H2 2016 45
Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H2 2016 46
Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 47
Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H2 2016 48
Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H2 2016 49
Congestive Heart Failure (Heart Failure) - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 50
Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H2 2016 51
Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H2 2016 52
Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H2 2016 53
Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia, Inc., H2 2016 54
Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2016 55
Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics, Inc., H2 2016 56
Congestive Heart Failure (Heart Failure) - Pipeline by Cell Therapy Limited, H2 2016 57
Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H2 2016 58
Congestive Heart Failure (Heart Failure) - Pipeline by Eli Lilly and Company, H2 2016 59
Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H2 2016 60
Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H2 2016 61
Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H2 2016 62
Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Limited, H2 2016 63
Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H2 2016 64
Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H2 2016 65
Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 66
Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H2 2016 67
Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2016 68
Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 69
Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H2 2016 70
Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 71
Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H2 2016 72
Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H2 2016 73
Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H2 2016 74
Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H2 2016 75
Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H2 2016 76
Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H2 2016 77
Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H2 2016 78
Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics, Inc., H2 2016 79
Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences, Inc., H2 2016 80
Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H2 2016 81
Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics, Inc., H2 2016 82
Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 83
Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H2 2016 84
Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H2 2016 85
Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H2 2016 86
Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 87
Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H2 2016 88
Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H2 2016 89
Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H2 2016 90
Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H2 2016 91
Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H2 2016 92
Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H2 2016 93
Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc., H2 2016 94
Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 95
Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H2 2016 96
Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma, Inc., H2 2016 97
Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H2 2016 98
Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 99
Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H2 2016 100
Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell, Inc., H2 2016 101
Congestive Heart Failure (Heart Failure) - Pipeline by Vichem Chemie Research Ltd., H2 2016 102
Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H2 2016 103
Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 104
Assessment by Monotherapy Products, H2 2016 105
Assessment by Combination Products, H2 2016 106
Number of Products by Stage and Target, H2 2016 108
Number of Products by Stage and Mechanism of Action, H2 2016 114
Number of Products by Stage and Route of Administration, H2 2016 120
Number of Products by Stage and Molecule Type, H2 2016 122
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2016 369
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H2 2016 370
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H2 2016 371
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H2 2016 372
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H2 2016 373
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H2 2016 374
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H2 2016 375
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H2 2016 376
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..8), H2 2016 377
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..9), H2 2016 378
Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2016 379
Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H2 2016 380

List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2016 22
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 24
Number of Products under Investigation by Universities/Institutes, H2 2016 30
Comparative Analysis by Late Stage Development, H2 2016 32
Comparative Analysis by Clinical Stage Development, H2 2016 33
Comparative Analysis by Early Stage Products, H2 2016 34
Assessment by Monotherapy Products, H2 2016 105
Number of Products by Top 10 Targets, H2 2016 107
Number of Products by Stage and Top 10 Targets, H2 2016 107
Number of Products by Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Top 10 Routes of Administration, H2 2016 119
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 119
Number of Products by Top 10 Molecule Types, H2 2016 121
Number of Products by Stage and Top 10 Molecule Types, H2 2016 121
  • Stroke - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 519
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2016, provides an overview of the Stroke (Cardiovascular) pipeline landscape.Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They m......
  • Critical Limb Ischemia - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 145
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2016, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet ......
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 168
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or ca......
  • Acute Coronary Syndrome - Pipeline Review, H2 2016
    Published: 09-Nov-2016        Price: US 2000 Onwards        Pages: 109
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Coronary Syndrome - Pipeline Review, H2 2016, provides an overview of the Acute Coronary Syndrome (Cardiovascular) pipeline landscape.Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high......
  • Ventricular Arrhythmia-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Ventricular Arrhythmia-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Ventricular Arrhythmia. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaboration......
  • Myocardial Ischemia-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Myocardial Ischemia-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Myocardial Ischemia. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acq......
  • Critical Limb Ischemia - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Critical Limb Ischemia - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Critical Limb Ischemia forecasted market share for ten years to 2023 segmented by seven major markets. In addition,......
  • Dilated Cardiomyopathy-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Dilated Cardiomyopathy-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Dilated Cardiomyopathy. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaboration......
  • Dyslipidemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Dyslipidemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Dyslipidemia Report is to understand the market and pipeline status of the drugs around the Dyslipidemia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs